Hemeoxygenase-1 in thyroid cancer progression

PICHEL, P.; PEROS, I.; RECIO, S.; CASTELLANO, L.; CURINO, A.C.; ALONSO, E.G.; FERNANDEZ CHAVEZ, L.; COLÓ, G.P.; ARÉVALO, J.; GANDINI, N.A.; MASCARÓ, M.; SCHWEITZER, K.; CARBALLIDO, J.; FACCHINETTI, M.M.

Evento virtual por pandemia COVID-19

Congreso; LXV Reunión Anual de la Sociedad Argentina de Investigación Clínica (SAIC); 2020

Sociedad Argentina de Investigación Clínica

Previous work from our group shows that Hemeoxygenase-1 (HO-1)is overexpressed in several types of tumor and the enzyme can belocated in cell cytoplasm and/or nucleus. This subcellular distribution is caused by the cleavage of the C-terminus of HO-1 by calpain1 (CAPN1), calpain 2 (CAPN2), cathepsin B (CTSB) and signal peptide peptidase (SPP). In thyroid cancer (TC), HO-1 potential utility asbiomarker remains underexplored. The aim of this work was to studyHO-1 expression in TC and its correlation with clinical-pathologicaldata. Tumor biopsies (N=64) and fine needle aspiration biopsies(FNAB) (N=22) were used to asses HO-1 expression by inmunohistochemistry (IHC) and inmunocytochemistry (ICC), respectively.In addition, mRNA expression of HO-1, CAPN1, CAPN2, CTSB andSPP were analyzed by using GEPIA2 and Kaplan-Meier Plotter databases in in silico assays. In TC biopsies, overexpression (OE) ofHO-1 by IHC was found in the tumor (T) respect to non-malignantareas to the tumor (NMT) (Mann Whitney test, p